PeptideBased Infection Therapeutics Market by Drug (Telaprevir, and Boceprevir),by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and OnlinePharmacies) and by Geography - Size, Share, Outlook, and Opportunity Analysis2018 – 2026
Excessive and inappropriate useof antibiotics is creating antibiotic resistance among affected population atpresent. Therefore, the urge of developing novel therapies in fightinginfections is increasing. A novel, peptide based therapies for treatinginfections has offered various advantages in terms of stability, safety,tolerance, possesses selective nature, effective with broad spectrum ofactivities and mechanisms. They also protect the host from pathogenic microbes,so also referred as host defense peptides.
Peptide Based InfectionTherapeutics Market – Drivers
Increase in number of pipelinedrugs is expected to drive peptide based infection therapeutics market. Forinstance, in September 2018, BioAegis Therapeutics Inc. started clinical trialsfor Phase 1b/2a study of recombinant plasma gelsolin (rhu-pGSN) inCommunity-Acquired Pneumonia (CAP), in Australasia and has observed reducedmorbidity and mortality in over 20 infectious and non-infectious disease animalmodels.
* The sample copy includes: Report Summary, Table ofContents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copyof this report: https://www.coherentmarketinsights.com/insight/request-sample/2185
Furthermore, LA JollaPharmaceutical Company is undergoing phase II clinical trials for LJPC-501, andis expected to complete study in April 2023. This drug can be used for treatingSeptic Shock.
Peptide Based Infection TherapeuticsMarket – Restraint
High cost of alternativetechniques in manufacturing of peptide drugs to avoid peptide degradation mayhamper the growth of the market. For instance, According to an articlepublished in Biomolecule 2017, utilization of techniques such as Liposomes,PEGylation, need to develop for effective peptide drug delivery have increasedthe overall cost of therapy and thus restraint the growth of the market.
Peptide Based Infection TherapeuticsMarket – Regional Analysis
On the basis of region, thePeptide Based Infection Therapeutics Market is segmented into North America,Latin America, Europe, Asia Pacific, Middle East, and Africa. North Americaexpected to show higher market attractiveness and domination over other regionsdue to new advancements in treatment such as peptide vaccines, and presence oflarge number of peptide manufacturing companies. In 2014-2015, AmbioPharm,Inc., a company of U.S., is manufacturing peptide based antifungals with betterefficacy. This company has also expanded its manufacturing units in America andChina to meet the demands.
Browse ResearchReport: https://www.coherentmarketinsights.com/ongoing-insight/peptide-based-infection-therapeutics-market-2185
Furthermore, high number ofmorbidity of infectious diseases is also driving the growth of market in U.S.For instance, According to World Health Organization (WHO) 2016 statistics, inU.S., number of new tuberculosis cases were 9,272 and number of new salmonellacases were 53,850.
Peptide Based InfectionTherapeutics Market – Competitive Landscape
The key players involved in thismarket are Vertex Pharmaceuticals Incorporated, Merck & Co., Inc. ParchemFine & Specialty Chemicals, AmbioPharm Inc., CoredentPharma International,GenScript, Sun Pharmaceutical Industries Ltd., Bharat Biotech, and Dr. Reddy’sLaboratories Ltd.
Buy-Now this researchreport: https://www.coherentmarketinsights.com/insight/buy-now/2185
AboutCoherent Market Insights:
CoherentMarket Insights is a prominent market research and consulting firm offeringaction-ready syndicated research reports, custom market analysis, consultingservices, and competitive analysis through various recommendations related toemerging market trends, technologies, and potential absolute dollaropportunity.
ContactUs:
mailto:sales@coherentmarketinsights.com
U.S.Office:
Name: Mr. Shah
CoherentMarket Insights 1001 4th Ave,
# 3200Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
